New Leaf has not created a formal advisory board for therapeutics
New Leaf
Named in 19 passages across 7 documents.
Mentions of New Leaf in the public Epstein records, with citations.
Being named in these documents is not an accusation or evidence of wrongdoing. This page reflects only what the public records literally contain, with citations to the original sources.
Where New Leaf appears
19 total
iell said. “I wanted to give everyone the experience of playing in Puerto Rico.” After the game, the Broncos set up a meet-and-greet between both team and an innovative idea came out of it. “They took care of us all weekend,” Cofiell said....
86th year, No. 23811 TUESDAY, DECEMBER 13, 2016 $1
TEXT-001-HOUSE_OVERSIGHT_014498.txt
p.1
View source release ↗
vestors. Patients are offered therapies that are more targeted to their disease, and benefit from improvements in efficacy and safety through increased life expectancy, improved quality of life, and a more rapid return to a fully productive...
am member joined the board, exited at 2.25x), Acadia Pharmaceuticals (NLV-II, NASDAQ: ACAD, exited at 2.5x) and Intercept Pharmaceuticals (NLV-II, NASDAQ: ICPT; anchored company’s IPO, NLV team member initially joined the company’s board, e...
…AQ: DRTX), and Ilypsa (Sprout IX, exited in sale to Amgen, 6.9x multiple). Established Private Companies: The New Leaf Team has played the role of lead investor in a large number of private investments. These have included Cerexa (NLV-I, ex...
…the opportunities have the greatest long term investment potential. It is these efforts that have allowed the New Leaf team to create some of the best performing portfolios of biopharmaceutical investments in the industry in the Sprout Fund...
unity to join the board of directors. An example of an investment that resulted from New Leaf’s focus on public market opportunities includes MEI Pharma (NLV-II, NASDAQ: MEIP), an investment the Fund Managers made to recapitalize the compan...
…vestments will be focused on small capitalization companies at the clinical or early commercialization stage. New Leaf’s focus on investment opportunities in small capitalization public biotech companies leverage the broad investment capabi...
…ts through IPOs in a broad range of market conditions. Examples of this type of later stage investment in the New Leaf portfolio include Acadia Pharmaceuticals (NLV-II, NASDAQ: ACAD, exited at 2.5x), Phase III, focused on psychosis associat...
primary asset(s) fall within one of the following categories: � � � Early and mid-clinical stage product programs targeting a well validated mechanism of action in a disease with significant unmet medical need. The therapeutic areas and spe...
al investments ahead of key risk inflection points, the Fund Managers expect to fund companies through the periods of greatest value creation to points where they will either become attractive targets for acquisition or partnership, or beco...
28 companies that will be predominantly domiciled in the U.S., but could include a small number of companies based in Western Europe or Canada. The Fund Managers intend to serve on the boards of directors for the majority of the companies i...
…nity for attractive returns. 10 CONTROL NUMBER 257 - CONFIDENTIAL II. THE TEAM NLV-III will be managed by the New Leaf team, which currently manages NLV-I, NLV-II, and provides sub-advisory services managing the remaining healthcare technol...
…cessfully executed this investment process over many years, and it is an integral part of the firm’s culture. New Leaf’s investment philosophy and process emphasize a team approach to maximizing investment returns, focusing the most appropr...
…cessfully executed this investment process over many years, and it is an integral part of the firm’s culture. New Leaf’s investment philosophy and process emphasize a team approach to maximizing investment returns, focusing the most appropr...
number of commercial stage companies with novel and clearly differentiated products targeting
IMAGES-007-HOUSE_OVERSIGHT_024020.txt
p.1
View source release ↗
Il. THE TEAM NLV-III will be managed by the New Leaf team, which currently manages NLV-I, NLV-IL, and provides sub-advisory services managing the remaining healthcare technology investments in the Sprout Funds. The team of six senior partne...
NLV-III will be managed by the New Leaf team, which currently manages NLV-I, NLV-IL, and
IMAGES-007-HOUSE_OVERSIGHT_024022.txt
p.1
View source release ↗
Leadership: NLV_ are leaders in biopharmaceutical investing across all stages and transaction types The New Leaf team is well positioned to continue to play a leadership role in the sector. Over the last two decades, the Fund Managers have...
Leadership: NLV_ are leaders in biopharmaceutical investing across all stages and transaction
IMAGES-007-HOUSE_OVERSIGHT_024045.txt
p.1
View source release ↗
…of an investment. Credit is given for each professional's role, and for each team member's ability to be a team player. New Leaf seeks to avoid “lone ranger” behavior and instead actively implements a team approach. The Fund Managers inten…
The New Leaf team applies a rigorous, systematic, fundamentals-driven approach to diligence
IMAGES-007-HOUSE_OVERSIGHT_024055.txt
p.1
View source release ↗
The New Leaf team applies a rigorous, systematic, fundamentals-driven approach to diligence on all new deals, which, in addition to assessment against the sector specific strategies, includes consideration of the following risk/ reward fact…
The New Leaf team applies a rigorous, systematic, fundamentals-driven approach to diligence
IMAGES-007-HOUSE_OVERSIGHT_024055.txt
p.1
View source release ↗
Also named alongside
Want context across all of these passages at once?
Ask the documents about New Leaf